EUVIMEDEUVIMED entdecken
Crossref

Integrative Proteomic and Lipidomic Analysis of Post-Myocardial Infarction Patients Treated With PCSK9 Antibodies and Statins.

Lukas Emanuel Schmidt, Sean Anthony Burnap, Bhawana Singh, Kaloyan Takov, Sylvain Losdat, Lore Schrutka, Lukas Galli, Konstantinos Theofilatos, Georg Otto, Christian Hengstenberg, Ioanna Tzoulaki, Irene Marthe Lang und 4 weitere

Open Access CRIS of the University of Bern · 01.04.2026

DOI: 10.48620/94734 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Access CRIS of the University of Bern, erschienen am 01.04.2026. Verfasst von Lukas Emanuel Schmidt und 15 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition is a potent cholesterol-lowering strategy. This study examined the effects of PCSK9 monoclonal antibodies (mAbs) and high-intensity statins beyond low-density lipoprotein cholesterol reduction, which are not fully defined, particularly in patients with acute myocardial infarction (MI).

Methods

Combined proteomics and lipidomics analyses was conducted on plasma from 265 patients with acute MI from the PACMAN-AMI (Effects of the PCSK9 Antibody Alirocumab on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction) randomized, placebo-controlled PCSK9 mAb trial and 34 patients without MI with hyperlipidemia from the Vienna Lipid Clinic registry, also receiving PCSK9 mAbs.

Results

Discovery proteomics revealed changes in apolipoproteins and increased PCOLCE (procollagen C-endopeptidase enhancer 1) levels in both the PCSK9 mAb and placebo groups after MI. UK Biobank data confirmed PCOLCE and PCSK9 upregulation as associated with statin use. Hepatoma cell experiments demonstrated a dose-dependent PCOLCE induction on statin treatment. Compared with placebo (statins only), PCSK9 mAb therapy resulted in greater reductions in APOB, APOE, APO C2, and APO C3, as shown by targeted proteomics. Mediation analysis indicated that these changes were largely explained by low-density lipoprotein cholesterol lowering. Lipidomics identified more pronounced reductions in cholesteryl esters, ceramides, sphingomyelins, phosphatidylcholines, triglycerides, and diglycerides in PCSK9 mAb-treated patients with MI. Results were largely consistent in patients without MI. However, levels of LPA (apolipoprotein[a]), the characteristic protein component of lipoprotein(a), remained unchanged in PCSK9 mAb-treated patients with MI, since a rise of LPA was observed in the placebo group post-MI.

Conclusions

Most apolipoprotein changes after PCSK9 mAb therapy after MI were mediated by low-density lipoprotein cholesterol lowering. Statin use is associated with increased circulating PCOLCE, with hepatoma cell experiments supporting a predominant hepatic origin. Combining PCSK9 mAbs with high-intensity statins mitigates post-MI increases in lipoprotein(a). Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT03067844.

Schlagwörter

PCSK9 inhibitionPCSK9 monoclonal antibodiesalirocumabstatinsacute myocardial infarctionapolipoproteinslipoprotein(a)LDL cholesterolplasma lipidomehyperlipidemia

Zitieren

APA

Schmidt, L. E., Burnap, S. A., Singh, B., Takov, K., Losdat, S., Schrutka, L., Galli, L., Theofilatos, K., Otto, G., Hengstenberg, C., Tzoulaki, I., Lang, I. M., Koskinas, K. C., Speidl, W. S., Räber, L., & Mayr, M. (2026). Integrative Proteomic and Lipidomic Analysis of Post-Myocardial Infarction Patients Treated With PCSK9 Antibodies and Statins. Open Access CRIS of the University of Bern. https://doi.org/10.48620/94734

Vancouver

Schmidt LE, Burnap SA, Singh B, Takov K, Losdat S, Schrutka L, et al. Integrative Proteomic and Lipidomic Analysis of Post-Myocardial Infarction Patients Treated With PCSK9 Antibodies and Statins. Open Access CRIS of the University of Bern. 2026. doi:10.48620/94734

BibTeX
@article{Schmidt2026,
  author = {Schmidt, Lukas Emanuel and Burnap, Sean Anthony and Singh, Bhawana and Takov, Kaloyan and Losdat, Sylvain and Schrutka, Lore and Galli, Lukas and Theofilatos, Konstantinos and Otto, Georg and Hengstenberg, Christian and Tzoulaki, Ioanna and Lang, Irene Marthe and Koskinas, Konstantinos C. and Speidl, Walter Stefan and Räber, Lorenz and Mayr, Manuel},
  title = {Integrative Proteomic and Lipidomic Analysis of Post-Myocardial Infarction Patients Treated With PCSK9 Antibodies and Statins},
  journal = {Open Access CRIS of the University of Bern},
  year = {2026},
  doi = {10.48620/94734}
}
Kostenlos starten →